Dr Reddys net profit up by 45 percent to Rs 663 crore for June quarter

"This quarter, we grew in most of our key markets and hope to continue this momentum with a sharper focus on performance," Dr Reddy's Laboratories Chief Executive Officer (CEO) and Co-Chairman G V Prasad said.

HYDERABAD: Dr Reddy's Laboratories on Monday posted a 45.31% rise in consolidated net profit at 662.8 crores for the June quarter.

The company had reported a net profit of 456.1 crores in the corresponding period of 2018-19.

Revenues during the period rose to 3,843.5 crores as compared with 3,720.7 crores in the year-ago period, Dr Reddy's Laboratories said in a regulatory filing.

"This quarter, we grew in most of our key markets and hope to continue this momentum with a sharper focus on performance," Dr Reddy's Laboratories Chief Executive Officer (CEO) and Co-Chairman G V Prasad said.

Read Also: Dr Reddy’s unveils generic version of Lyrica capsules in US for treating neuropathic pain

The Hyderabad-based firm said that with effect from 1 August, Erez Israeli will be elevated as the CEO of the company.

Prasad will continue as the co-chairman and managing director, and Israeli will continue to report to him, it added.

Since joining the company as the chief operating officer in April 2018, Israeli has spearheaded the transformation agenda of the organization by ensuring clear focus and strategy, setting foundations for sustainable financial growth and leading business delivery, the drug firm said.

His appointment as the CEO will help propel the organization's growth agenda forward, it added.

Read Also: Dr Reddy’s anticipates USFDA inspection of Srikakulam plant by year-end